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Abstract
Many studies now produce parallel data sets from different omics technologies; however, the task of interpreting the
acquired data in an integrated fashion is not trivial. This review covers those methods that have been used over the past
decade to statistically integrate and interpret metabolomics and transcriptomic data sets. It defines four categories of
approaches, correlation-based integration, concatenation-based integration, multivariate-based integration and pathway-
based integration, into which all existing statistical methods fit. It also explores the choices in study design for generating
samples for analysis by these omics technologies and the impact that these technical decisions have on the subsequent
data analysis options.
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Introduction
In recent years, an explosion has occurred in the acquisition of
biological data through the use of so-called ‘omics’ techniques.
Whilst many different omics technologies are now featured in
the literature, the most frequently used omics are genomics,
transcriptomics, proteomics and metabolomics.
Early studies tended to use only a single omics technology for
the analysis of a set of samples, and there have been many ef-
forts to standardize the reporting of preparation, data and data
analysis pipelines for each individual data type [1–4]. However,
increasingly, studies now include measurements from multiple
omics techniques. The main impetus for data integration is that
through these integrated data sets, an improved understanding
of the underlying biology is obtained, to be better able to predict
a response variable and to gain further insight into mechanistic
aspects of the system. This review will show that metabolomics
and transcriptomics produce data sets with complementary in-
formation, and to fully use these data, it is necessary to perform
integrative steps in the data analysis, as opposed to separate
analyses of the data sets and presentation of these separate ana-
lyses as a single study in the same publication.
When transcriptomic and metabolomic data are integrated,
there is no direct association between metabolite and tran-
script. It is not possible to link each transcript to a metabolite or
vice versa. This is in contrast with transcriptomics and prote-
omics, where most transcripts can be mapped to a single pro-
tein and then the obtained profiles compared (although there
can still be significant deviations in the observed effects [5, 6]
for a variety of biological reasons). This complicates the data
analysis and implies that more complex statistical techniques
must be used to find the relationships presumably inherent in
the data set. Despite all this, transcriptomic–metabolomic inte-
gration is clearly a powerful combination, the metabolome pro-
viding phenotypic measurements to which we can anchor the
global measurements of the transcriptome.
Taking into account these difficulties, it is unsurprising that
the complexity and effort needed for effective data integration
is often underestimated. An interesting estimate of the amount
of effort required to integrate data sets has been performed by
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Palsson [7], the outcome of which encourages further consider-
ation of this key stumbling block.
We here review the techniques that have been applied for stat-
istical data integration of metabolomics and transcriptomics data.
Study design for integrated data analysis
When multiple omics technologies are applied within a single
study, there are several possible study designs. The choice of
study design is important, as it will have many implications
throughout the study, in particular with regard to the data ana-
lysis. The most common study designs are shown in Figure 1.
The repeated study (Figure 1A) can often be the most con-
venient approach, producing a set of samples for the first omics
and then repeating the experimental protocol to generate the
samples for a second omics (or conducting the same protocol in
multiple laboratories to generate different sample sets).
However, this will introduce batch effects into the data analysis
as noted by Tillinghast [8]. Batch effects, when occurring in
large studies with a single omics technology, can be corrected
for by using statistical methods, such as simply centring the
data from each batch separately before combination or other
more complex approaches as discussed by Leek et al. [9].
However, when multiple omics technologies are applied through
separate experiments, there is no possibility to apply batch cor-
rection. The repeated study design does, however, have some ad-
vantages, in that measurements could be considered statistically
independent, or independent tests of the same hypothesis [10].
The other designs shown in Figure 1 are more similar, in
that they all are assumed to produce data without batch effects
between the different omics data sets (within omics batch ef-
fects may still be present, especially if large numbers of samples
are run over a period of time). In terms of data integration, the
ideal situation is to have samples originating from the same
biological source material. For instance, a piece of tissue may be
cut into two sections and one used for metabolomics analysis,
whilst the other is used to extract RNA. We will term this a split
sample study design (Figure 1B).
Usually, the deciding factor concerning the choice of study
design, is feasibility, e.g. whether samples for multiple omics
can be taken from a single biological replicate or source. For in-
stance, in case of an in vitro study, if the intracellular extract is
to be analysed by metabolomics and the isolated RNA by tran-
scriptomics, a separate sample is needed for the metabolomics
analysis, as the RNA extraction process and the sample prepar-
ation protocol of a cell pellet for metabolomics are mutually ex-
clusive. In this case, a replicate-matched study design (Figure
1C) may be used to generate the matched samples from differ-
ent biological replicates from within the same experiment.
When performing a replicate-matched study, it is important to
randomize every aspect of the study between the samples being
prepared for each omics technology, so as not to introduce any
bias between the profiles obtained by each technology. A
replicate-matched study differs critically from a repeat study, as
the samples for both omics are produced/obtained at the same
time, and thus the introduction of batch effects is avoided.
Alternatively, one may choose to use different fractions of
the biological system for different analyses. We term this a
source-matched study (Figure 1D); the clearest example of this
is seen in animal studies, where blood or urine may be taken for
metabolomics to be matched with RNA profiles from the af-
fected tissue. Source-matched studies can also be performed
in vitro, for instance, if cell material is used for transcriptomics
analysis and the cell media for metabolomics.
Figure 1. Four different study designs commonly used for multi-omics studies.
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Given a free choice of study design, the split-sample study
would be the best to use, followed by the replicate-matched
study. Source-matched studies can be useful as shown later,
but it must be carefully considered how any links found be-
tween the two data sets will be interpreted. Repeated study de-
signs are best avoided if possible to circumvent the inherent
batch effects.
Taxonomies of data integration
In [11], Ebbels suggests that there are three levels of data inte-
gration: conceptual integration, statistical integration and
model-based integration. These are shown in Figure 2, panel A.
Conceptual integration refers to the situation where multiple
omics data sets are analysed separately, and then, the resulting
conclusions are matched without any further analysis of the
data set as a whole, such as in [12, 13]. This approach can pro-
duce valuable insights; however, it will also miss associations
that can only be found when both data sets are analysed to-
gether. Statistical integration is the most common form of inte-
gration applied to transcriptomic and metabolomic data sets,
where statistical associations are sought between the elements
from the different data sets. Model-based integration is cur-
rently an unobtainable ideal in most situations in which global
Figure 2. Methods for omics data integration: Panel A shows the three main types of integration as per [11]. Panel B elaborates on the different methods for statistical
data integration, dividing them into four approaches, which are reviewed separately in this article.
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omics data are acquired, as there are not yet enough data to de-
termine all the model the system based on a priori biological
knowledge would pre-exist before the experiment, and then the
data obtained from the experiment could be compared param-
eters needed (concentrations, rate constants, interactions, etc).
In this approach, a computational or mathematical model of
with that predicted from the model. The model might, for in-
stance, be a fully parameterized metabolic network for the bio-
logical system under study.
In this article, we will focus on examples of statistical data
integration, and further classify them into four subgroups (see
Figure 2, panel B). Firstly, correlation-based integration seeks to
find correlative links between elements of one data set and
elements from the other. Secondly, data set concatenation-
based integration methods group together those approaches
that concatenate the gene and metabolite measurements into a
single table to perform an integrated analysis. However, both
techniques are severely limited in their scopes. Correlation
often fails because of different time scales of change, and con-
catenation-based methods have to deal with the different
underlying distributions of the data from the contributing tech-
nologies. Thirdly, multivariate-based integration uses vari-
ations on standard multivariate techniques such as partial least
square (PLS) and principal component analysis (PCA) to model
the data and either to perform predictions or to find relation-
ships between variables/samples and visualize the variation in-
herent in the data. The last group is a class of methods that
attempt to integrate the data using existing biological know-
ledge through metabolic pathways as predefined in databases
such as KEGG [14] and Wikipathways [15]. We call these tech-
niques pathway-based integration. These pathway-based inte-
gration techniques are distinct from modelling efforts, as rather
than studying reaction fluxes, they instead map, in an auto-
mated manner, the measured metabolites and transcripts to
pathways and find those where there is statistical evidence of a
significant change in their behaviour between two conditions,
or a correlation between pathway behaviour and a phenotypic
end point of interest.
These four categories can be related to the split between
’biology-driven strategies’ and ’data-driven strategies’ identified
by Thomas and Ganji [16], in that their ’biology-driven strat-
egies’ cover studies using a purely conceptual analysis, which
are not reviewed here, as well as those using pathway-based in-
tegration. Meanwhile, their ’data-driven strategies’ are equiva-
lent to the other three categories presented here.
Correlation-based integration
One of the simplest ways to explore multi-omics data in an inte-
grative way is to explicitly set out to look for correlative links be-
tween the data sets. Correlations have frequently been used to
examine the associations between transcriptomic data and
metabolomics measurements. There are many ways to assess
the correlation of two sets of measurements, the most common
of these being Pearson’s and Spearman’s correlation for para-
metric and non-parametric data, respectively.
Naively, one expects metabolites to correlate with those
genes with which they have associations; however, this is not
always the case. While on the one hand, Urbanczyk-Wochniak
found more than double the number of significantly correlated
metabolite–transcript pairs than would be expected by chance
in potato tubers [17], and Fendt et al. [18] quantified transcripts,
proteins and metabolites in yeast and other species on perturb-
ations (for instance single enzyme modulations) and showed an
inverse relationship between the log fold change of a metabolite
and the log fold change of the protein or transcript catalyzing
the reaction. They also found a great deal of variation in the cor-
relation’s strengths, with a more significant trend in the correl-
ations between substrates and enzymes than between reaction
products and enzymes. On the other hand, ter Kuile and
Westerhoff [19] found that fluxes through steps in the biochem-
ical pathways did not correlate proportionally with the concen-
trations of the corresponding biochemical enzymes, and
Moxley et al. [20] also report low correlation coefficients between
transcripts of metabolic enzymes and related metabolite fluxes
(r ¼ 0.07–0.8) in yeast.
More concerningly for pure correlation-based approaches,
Bradley [21] noted that both the direction and magnitude of cor-
relation between metabolites and related genes could vary sig-
nificantly between experimental conditions.
As well as using standard correlation coefficients, such as
Pearson’s or Spearman’s, there are also other methods for
measuring correlation; the Goodman and Kruskal gamma test,
which only takes into account the up/down regulation of each
metabolite/gene, e.g. [22]; robust linear models, which look at
each transcripts’ ability to predict each metabolite [23]; and par-
tial correlations [24, 25], which evaluate those correlations that
are independent of the other colinear measurements. For in-
stance, what is the independent correlation of gene A and me-
tabolite B, given that they are both correlated to gene C, can be
calculated through a partial correlation computation.
In many experimental designs, we know that the changes in
the metabolome and the transcriptome will not be simultan-
eous, and therefore it will be best to obtain a time course of
samples for each omics. In these cases, it has been shown that
by firstly aligning the data through techniques such as Dynamic
Time Warping will help the detection of associated metabolites
and transcripts [26].
In mammalian systems, data integration is often performed
on source-matched data sets, where the RNA and metabolomics
samples were acquired from different tissues. This complicates
the expected correlation patterns. For instance, linking plasma
metabolic changes to liver transcript changes in a source-
matched study of fenofibrate and fish oil treatments in mice
[27]. Lu et al. found that the expression of genes involved in fatty
acid metabolism were associated with levels of plasma choles-
terol and phosphatidycholine.
This section shows that a straightforward application of
Pearson or Spearman correlation has many potential problems
and is not overly suited to the task of metabolomic–transcrip-
tomic data integration. Those elements that are known to be
closely related in the pathways, often do not show a correlative
link, while correlations can also occur at great distances across
the network. More work needs to be undertaken to see if partial
correlations can aid the identification of the most direct con-
nections. There are also issues of time that obscure the correla-
tive links between transcriptomic and metabolomic samples
taken at matched time points, with metabolomic changes being
connected to a transcriptomic changes at a much earlier time
points and vice versa. In cases where the time course data exist,
alignment will be an important step before the correlative asso-
ciations are evaluated.
Data set concatenation-based integration
Data set concatenation-based integration methods are some of
the earliest and conceptually some of the simplest methods for
combining data sets across multiple omics platforms into a
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single model. By concatenating the data tables produced by
each omics technology into a single data table, standard tech-
niques such as Self-Organizing Maps [28, 29], K-means cluster
analysis [30] or random forests [31] can be applied. Daub [32]
presented MetaGeneAlyse, a web service that can run many of
these standard methods on concatenated metabolomics–tran-
scriptomics data sets.
One complication in concatenative data integration occurs
when the data sets that are to be integrated have vastly different
sizes. For instance, if the metabolomics measured 100 metabol-
ites, compared with 10 000 transcripts, any concatenative model
would be dominated by the patterns seen in the gene data. To
overcome this problem, one can apply block scaling factors to
each block, weighting each variable by the inverse of the number
of variables in the block [33], introducing the assumption that
every block should have equal weight in the final model.
As well as having vastly different sizes, metabolomics and
transcriptomics data sets are obtained from vastly different
technologies, which implies that the data sets have different
structures, different patterns of expected values, different dis-
tributions of underlying noise and different variances.
Consequently, obtaining integrative links between metabolo-
mics and transcriptomics data from a simple concatenated data
set is not straightforward. It is thus normal that when clustering
a concatenated data set, elements from each data set will tend
to cluster with other elements of their own data set, obscuring
any inter-omics associations. This problem can be particularly
acute, if the concatenated data set is being processed by PCA,
PLS or another variance maximizing algorithm, as sources of
analytical variation will typically be selected in the first compo-
nents. As the sources of analytical variation will vary between
the two halves of the concatenated data set, this will lead to a
fragmented model, which will not inform about the joint vari-
ation seen in the data sets. More advanced methods, as
described in the multivariate models section, are needed to
counter this problem.
Using tools such as iCluster [34], which cluster the data sets
both together and independently, may allow for some of these
restrictions to be circumvented, although more research needs
to be done to evaluate this. The effect of these underlying distri-
bution differences can be minimized by removing the elements
with little or no signal, where the structure of the noise will
have a much larger impact, and through applying a common
normalization and scaling to the data. Even so, it is not possible
through preprocessing to remove these effects entirely. In sum-
mary, whilst concatenated approaches are simple to imple-
ment, their added value is inherently limited by the concerns
documented above, and therefore, we believe that the other op-
tions presented in this review are more suited to the task of
metabolomic–transcriptomic data integration.
Multivariate-based integration
Moving beyond the relatively simple and straightforward meth-
ods described in the previous two sections, multivariate model-
ling will now be explored. These methods are simultaneously
much more powerful for data integration and much more com-
plex, and many of them have been applied in the chemometrics
domain before coming to the attention of bioinformaticians.
The two most common multivariate techniques are PCA and
PLSs, which are both well covered in [35]. Both PCA and PLS are
particularly useful for data sets with high levels of colinearity,
as is the case with omics data, where many genes or metabol-
ites will have similar (colinear) profiles. When using
multivariate models for omics data integration, one may seek to
use one data set to predict aspects of another data set or to find
the ’covariance’ associations between the two data sets. Unlike
the work in the previous section, here the data sets are used in
a non-concatenative way, keeping the metabolomics and tran-
scriptomics data sets in separate blocks or dimensions within
the model.
The earliest example of PLS models being used for
metabolomic–transcriptomic data integration is from Griffin
et al. [36], who integrated metabolomics and transcriptomics
data from two different strains of rats treated with orotic acid.
They used the metabolomic nuclear magnetic resonance (NMR)
spectral regions as the x for the model, and the transcriptomics
data as the y to be predicted. Once a model had been con-
structed, they examined the metabolites that were associated
with various genes through the loadings from the model.
Alongside other analyses, these models helped them to explain
why one strain of rats was more susceptible to fatty liver dis-
ease following dosing. In a later paper [37], these authors re-
versed this process by using transcriptomics profiles as the x
block and the NMR-integrated peaks as the y, to study the links
between metabolomic and transcriptomic changes in rats fol-
lowing phenobarbital exposure, finding changes in hepatic me-
tabolism, oxidative stress and cyctochrome P450 induction.
There are also several examples where PLS is used with tran-
scriptomic profiles as the x and measurements of two or three
targeted metabolites as the y [38, 39]. Sparse regression models
have also been used by Jauhiainen et al. to predict the metabolic
profile from the transcriptomic profile in a similar manner [40].
Using Griffin’s approach, it is necessary to define which of
the data sets will be used as the x and which as the y, and these
two are then non-equivalent in the model. This is not ideal for
those data integration studies, where the mutual relationships
between metabolites and transcripts are to be studied.
Therefore, a more natural method to use in these situations is
an extension of PLS, called O2PLS. In this algorithm, the x and
the y are symmetrical, so the assignment of which data set will
be x and which will be y is inconsequential. O2PLS extends the
standard PLS model with one block modelling the associations
between x and y, then one block each modelling the remaining
modelable parts of x and y separately and then as before the
unmodelable residuals (see Figure 3).
O2PLS has been applied by Rantalainen et al. to metabolomic
and proteomic data sets from a human prostate xenograft
model in mice [41]; by Eveillard et al. for examining liver
transcripts and blood plasma metabolites after di(2-ethylhexyl)-
phthalate exposure in humans [42]; by Grimplet et al. for com-
paring metabolomics, transcriptomics and proteomics data sets
from grapevines [43]; and by Bylsojö et al. for integrating
metabolomics and transcriptomics data sets from populus tree
crosses and with the addition of proteomics data from hybrid
aspen trees [44, 45].
Through O2PLS modelling, it becomes possible to obtain the
percentage of variance of each omics data set that is modelable
by the other data set. Using this approach with metabolomics,
transcriptomics and proteomics data, Bylesjö et al. [44, 45] found
that approximately one-third of each data set was modelable
from the other data sets. This work reinforces that there is
much in each data set that is unique to that data set and cannot
be simply linked to parts of the other data sets. This helps us to
understand why it is often difficult to find as many associations
between data sets as one might naively expect.
Related to these methods is another subclass called ’multi-
block methods’, where the different omics (or other data) are
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treated as different blocks in the model and thereupon com-
bined. The simplest of these methods is consensus PCA, which
was first applied to metabolomics and transcriptomics data in-
tegration by Heijne et al. [46]. Consensus PCA performs a stand-
ard PCA analysis on data that is split into blocks of variables (for
instance, a block of transcript measurements and a block of me-
tabolite measurements) and undergoes a block normalization
beforehand. In addition to the standard scores and loadings,
this method produces super weights, which indicate how the
blocks are related to each other [47]. These super weights gener-
ated extend this method beyond a simple PCA on a concaten-
ated data set, as was seen previously. Heijne et al. [46] uses this
method to integrate data sets obtained from rats with chem-
ically induced hepatic necrosis in a source-matched study
examining blood and urine metabolomics alongside liver tran-
scriptomics. The consensus PCA model produces a scores plot
showing the variation of the samples across the combined data
set, and then evaluates the metabolites and genes that are most
important to the separation. The interpretation and visualiza-
tion of these models was extended by Hassani et al. [48], who de-
veloped a range of plots and illustrated these on a five-block
data set containing genomic (in this case, not transcriptomic
but Amplified Fragment Length Polymorphism genetic finger-
printing) and Fourier Transform Infrared metabolomics data
along with phenotypic end points.
There also exists a selection of multiblock PLS methods that
have been applied to transcriptomic–metabolomic data [49],
such as Li et al. used in a complex pipeline to identify liver tox-
icity pathways in HepG2 cells after exposure to free fatty acids
and tumour necrosis factor-alpha. However, as yet, no work has
compared this approach with other more standard approaches
for identifying pertinent pathways.
More recently, a consensus form of the Orthogonal Partial
Least Squares Discriminant Analysis (OPLS-DA) method was intro-
duced by Boccard et al. [50] and tested on among others, data from
metabolomics, transcriptomics and proteomics experiments with
the NCI60 cell lines, with the results in this case validated through
bootstraping. In all three test cases, the combination of the differ-
ent omics data sets was found to be useful to achieve coherent
biological interpretations. The main advantage of consensus
OPLS-DA over O2PLS is that it can cope with more than two blocks
of data and treats all these blocks identically; however, the model
does not provide information about the interrelated features be-
tween the data sets, but instead regresses all the data against a
class variable (discriminant analysis).
Another alternative to the multiblock methods are multiway
methods. Here, the multiple blocks are stacked to produce an N-
dimensional data set. One example of such a multiway method
is N-PLS, which Conesa et al. [51] applied to the data from [46].
As well as integrating transcriptomics and metabolomics data,
they also include physiological end points, which then form an
additional dimension. The authors are able to interpret the toxi-
cological meaning of the components in the models built, and
between 61 and 70 of the 99 genes determined in the original
paper were identified by their method.
Hierarchical models also allow for the integration of differ-
ent data types. In these models, the individual data sets first
undergo a standard PCA or PLS-DA modelling step, before the
scores from the first n components of these models are com-
bined as the inputs to a further PCA or PLS-DA modelling step.
In terms of metabolomic and transcriptomic data integration,
this approach has been applied by Spicker [33] to combine three
data sets; clinical chemistry, transcriptomics and metabolomics
from rats dosed with three toxicants. They compared the mod-
els built through this hierarchical process with those built from
a concatenative approach, and concluded that the hierarchical
approach was better, in that it led to improved class separation.
The final multivariate model-based method we review, is ca-
nonical correlation analysis (CCA), which has been applied to
transcriptomics and gas chromatography–mass spectroscopy
metabolomics data from Escherichia coli undergoing a stress re-
sponse by Jozefczuk et al. [30]. In CCA, one searches for linear
combinations of variables from one block that correlate with
linear combinations of variables from the other block. The canon-
ical variate pairs are then reported, along with their significance,
and the linear combinations can be visualized similarly to a PCA
loadings plot. Jozefczuk, having limited the inputs to those genes
and metabolites involved in primary metabolism found, with one
exception (the mqo gene which grouped with TCA-cycle metabol-
ites), the strongest associations grouped only metabolites from
the same pathway without linking them to any genes. A free R
package, called integrOmics [52], implements CCA.
In summary, there are many options available to researchers
wishing to use multivariate modelling for data integration;
however, the choice of an appropriate method and the inter-
pretation of the resulting models is complex. In our opinion, the
field is lacking in comparison work, which evaluates these op-
tions against each other and compares the results obtainable
from each. A key challenge is to produce tools that will make
the methods not only usable, but also interpretable and easily
applicable by non-experts, alongside further investigation into
the limitations and advantages of each of the methodologies
and their accompanying visualizations. If these objectives are
met, then tools such as O2PLS could become powerful parts of
the standard toolkits for integrative omics data analysis.
Pathway-based integration
When integrating transcriptomic and metabolomic data, we
often wish to interpret these data against the backdrop of the
Figure 3. O2PLS models—the makeup of a standard O2PLS model for metabolomic–transcriptomic data integration, showing the different matrices involved.
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existing biological knowledge pertaining to how these entities
are linked. Much of this information is contained in pathway
databases available online. The use of these pathway databases
to examine the connections between genes that respond in a
particular way to a stimulus is well established, with a wide
range of statistical tools to examine the over-representation
and enrichment of pathways available.
The extension of these methods to metabolomics data is in-
creasingly available, through tools such as Metabolite Set
Enrichment Analysis [53] or the metabolite set analysis option
in ConsensusPathDB [54].
The integration of transcriptomics and metabolomics data
through pathways can be approached through several tools and
methods. Some early work by Cavill et al. [10] took publicly
available data from the NCI60 set of 57 cancer cell lines, where
baseline profiles of untreated cells had been measured using
metabolomics and transcriptomics through a repeated study. It
was examined how the baseline, untreated profiles of the cells
correlated to the cell line’s sensitivity to a range of 118 potential
chemotherapeutics. Focusing firstly on the genes and metabol-
ites that were correlated to a set of platinum drugs, it was found
that there was a great increase in sensitivity to pathways by
combining both omics data sets. The original integration ap-
proach applied took advantage of the repeated study design, as
it could be assumed that the metabolite measurements are
statistically independent of the gene measurements. Integrated
Molecular Pathway Level Analysis (IMPaLA) [55] implements
this method as a freely available web-based tool. In addition to
this joint over-representation analysis, IMPaLA also offers
Wilcoxon enrichment, where two values are supplied for all
measured entities, and then pathways are examined based on
whether the mean difference between the two values is signifi-
cantly different from 0. More recently, IMPaLA has been
updated to use Fisher’s method for combining P-values from
multiple tests of the same hypothesis [56], making it more ac-
curate when applied to non-repeated study designs. Kaever
et al. [57] have also explored using this and similar methods for
the combination of P-values from independent (repeated study)
and dependent (all other study designs) data sets and de-
veloped a tool MarVis pathway that imbeds this into metabolo-
mic/transcriptomic pathway-based data integration [58].
One commercially available tool MetaCore (GeneGo Inc.) has
been used in several studies [59–61]. In MetaCore, the pathway
ranking with metabolites and genes is calculated by taking the
minimum P-value from the separate omics analyses.
Another commercially available tool Ingenuity IPA also per-
forms integrated analysis, where it sorts the pathways based
on the sum of the –log (P-value) across all data sets. This is
equivalent to the independent combination of P-values seen in
the original IMPaLA.
Other tools available for joint pathway analysis are
PathVisio [62], Paintomics [63], InCroMAP [64] and INtegrative
Meta-analysis of Expression data (INMEX) [65], all of which pro-
duce a joint pathway P-value by totalling the number of differ-
entially expressed genes and metabolites and combining this
with the total number of measured genes and metabolites.
INMEX also produces a topology-based ranking of pathways,
where certain genes/metabolites are evaluated as more crucial
because of their position in the network and are therefore
weighted more heavily in the calculation.
The method for generating a joint P-value in the pathway
analysis will have a large impact on the pathways reported as
differentially expressed. The different approaches currently
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Paintomics, the genes and metabolites are treated as equivalent
entities, then if a pathway contains many more genes than me-
tabolites, the significance of the genes will overwhelm the sig-
nificance of the metabolites. This is shown in Pathway A in
Table 1, where it is clear that the all entities equal strategy
misses the significance of this pathway in the metabolomic
data. Because many pathways are indeed imbalanced in one
direction or the other, this is an important consideration.
MetaCore uses the minimum P-value from either transcriptom-
ics or metabolomics analyses, while the original IMPaLA and
Ingenuity calculate the significance of each pathway in the
genes and the metabolites separately and then use the assumed
statistical independence to combine these values, whereas the
updated IMPaLA and MarVis [58] use Fisher’s method to combine
the P-values, treating the tests as repeated tests of the same hy-
pothesis. Pathway C in Table 1 shows a situation where the path-
way is significantly changed in both omics data sets. Here, all
measures will declare the pathway significant; however, the level
of significance varies by some orders of magnitude.
Another key consideration in performing over-
representation-based pathway analysis, which most of these
tools provide, is the composition of the background list. The
background list should contain all the entities that were meas-
ured, irrespective of whether they were deemed statistically sig-
nificant between the conditions. These background lists are
crucial to the analysis, and omitting a background list will result
in a different list of significant pathways. With transcriptomics,
such a background list is easy to obtain during the processing of
the data. However, for metabolomics data, full assignments are
rarely performed, and so many of the peaks that are tested for
significance will be unassigned. In addition, there are two key
biases that will affect the pathway analysis results. Firstly, the
measured metabolites will be biased towards certain groups
and pathways, depending on the analytical method used. For
instance, amino acids are easy to assign from NMR spectra, and
therefore a larger proportion of the identified (and potentially
significant) metabolites will be amino acids than would be ex-
pected if one picked metabolites to assign at random. Without a
background list stating this bias, pathways involving amino
acids will always be significantly over-represented. Secondly, in
metabolomics, identifying metabolites in the spectra can take a
considerable amount of time from a skilled researcher, and
often studies will only invest the time to identify the metabol-
ites that are altered between experimental conditions, leading
to further bias in the list of identified metabolites from a data
set. One initiative that would meet this need, would be a public
resource of well-assigned examples from a selection of fre-
quently used sample types, cell lines, tissues, biofluids, etc,
measured on a range of metabolomic platforms and prepared
under different protocols, so that baseline lists of measurable
metabolites would be available for many situations. As an inter-
mediate step, we encourage researchers to publish the back-
ground lists used in their metabolomics pathway analysis as
supplementary information, to not only enable the community
to reach a consensus as to the optimal background list for each
sample type—analytical platform pair—but also to provide ad-
equate information for the analysis to be reproduced.
Finally, the results from the pathway analysis will also be af-
fected by the mapping between identifiers. Different identifiers
of genes/metabolites have many-to-many relationships with
identifiers in other naming systems, and this problem can be
acute with metabolomics data. For instance, in the case of lac-
tate and KEGG identifiers (see Table 2), there are three KEGG
identifiers that relate to lactate, C00186 the identifier for L-
lactate (S-lactate), C00256 the identifier for D-lactate (R-lactate)
and C01432 the identifier for Lactate. Whether these chiral me-
tabolites are distinguishable depends on the details of the ana-
lytical platform. Because they will have the same mass, often
specially selected columns need to be used in mass spectrom-
etry to make sure they elute at different times. Imagine that a
lactate peak has been measured without the capability to dis-
criminate between the L and D form and found to be signifi-
cantly different between conditions. In humans, the lactate
pool contains mostly L-lactate, but there is also a measurable
amount of bacterial produced D-lactate [66] that can be metabo-
lized by endogenous human enzymes found in the pyruvate
metabolism pathway in KEGG. Because, in this case, the meas-
urement is known to be of a pool of both isomers, one may
choose to map the lactate peak measurement to the identifier
for Lactate (C01432); however, this identifier is not present in
any KEGG pathways (see Table 2), so then this peak will then
have no influence on the pathway analysis. If one maps the
measurement to both D-lactate and L-lactate, then the pyruvate
metabolism pathway that contains both of these isomers, will
appear to have two significant metabolites from one significant
peak, and therefore will have a chance of appearing falsely sig-
nificant. In this case, mapping to L-lactate alone is the best op-
tion, as L-lactate is present in all the KEGG pathways in which
D-lactate is present, and additionally, this matches the biolo-
gical reality that the lactate pool is mostly L-lactate. However,
there is no optimal rule for the general case, and so, for each
similar case, the possibilities must be evaluated by hand, taking
into account in which pathways a particular identifier is present
(and re-evaluated when pathway databases are updated). An
additional complication is caused by peaks that are obtained
from overlapping metabolites, or which have ambiguous as-
signments. Again, publication of these mapping decisions as
supplementary information will greatly benefit the community
and the reproducibility of work.
Future prospects
There have been two recurring messages throughout this re-
view. Firstly, that the direction and strength of associations be-
tween metabolites and gene expressions vary strongly between
experimental conditions, because of the nature of the complex
networks in which the gene expressions and metabolites are
embedded. Secondly, that these associations are hidden by the
Table 2. Lactate identifier mappings with the KEGG pathways containing each identifier
Measured Metabolite KEGG id KEGG pathways
All lactate L-lactate C00186 Glycolysis/gluconeogensis; pyruvate metabolism; propanoate metabolism; styr-
ene metabolism; metabolic pathways; biosynthesis of secondary metabolites;
microbial metabolism in diverse environments; HIF-1 signalling pathway
D-lactate C00256 Pyruvate metabolism
Lactate C01432 None
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noise and variance structure inherent in each data set and often
not as abundant as one would naively expect. This conversely
leads to the positive observation that the different data sets
have much complementary information content, and therefore
integrated analyses have the potential to reveal much more of
the biology than the total of the separate analyses.
As multi-omics studies become increasingly financially and
technically feasible, the application of these methods will con-
tinue to expand and will need to develop. We imagine that the
correlation and concatenative methods will continue to be the
first port of call for many researchers, because of the simplicity
and familiarity of the methods from single-omics data analysis—
however, as observed above, these analyses have many failings
and can only give limited insights into these data sets.
Multivariate methods can generate valuable insights into the
amount and content of the overlapping information contained in
complementary omics data sets, along with strong predictive
models for phenotypic end points. However, the tools are not
often designed to be user-friendly, and furthermore, the inter-
pretation of these models is complex. Choosing which model to
best apply can be bewildering, and there exists a myriad of fac-
tors (such as scaling) that can significantly affect the results,
making their application even harder. However, we feel that
these methods have incredible potential, and the pay-off from in-
vesting the time to become an expert will be substantial for sci-
entists with the inclination. For biologists, the pathway-based
methods are the most intuitive and give ample relevant informa-
tion towards interpretations of the data. However, it is important
to note, that because these methods are based on existing path-
way knowledge, they can never be used to discover de novo gene-
metabolite associations, and so there will continue to be a need
for other techniques to explore these links, especially outside the
relatively well-explored domains of model species.
Returning to the study designs presented at the start of the
article, it is clear that the study design chosen impacts the opti-
mal analysis type. For instance, O2PLS is best suited towards
split sample data, where the joint information content between
the data sets is maximized, while in our experience with re-
peated studies, the overlapping information is often insufficient
to generate a robust model. Importantly, in writing this review,
it was often noted that it was difficult to determine the study
design used from the descriptions of the methods in the litera-
ture. Given the strong impact of study design choice on the opti-
mal analysis, this is concerning. We believe that the impact of
the study design on multi-omics integration methods should be
further explored to fully understand how the different methods
behave and where misleading results may appear.
Overall, the outlook for the application of multi-omics stud-
ies is bright, because of a growing set of methodologies and
tools in place for the analysis and interpretation. This will un-
doubtedly lead to many new advances in systems understand-
ing of biology.
Key Points
• Transcriptomic and metabolomic data sets contain
complementary information, so it is important that
statistical data integration is performed.
• Some simpler data integration methods do not work
because of the inherent differences in the distributions
of data points in the data sets because of the underly-
ing analytical technologies.
• Study design matters for the data integration steps.
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